IN2014CN00414A - - Google Patents
Info
- Publication number
- IN2014CN00414A IN2014CN00414A IN414CHN2014A IN2014CN00414A IN 2014CN00414 A IN2014CN00414 A IN 2014CN00414A IN 414CHN2014 A IN414CHN2014 A IN 414CHN2014A IN 2014CN00414 A IN2014CN00414 A IN 2014CN00414A
- Authority
- IN
- India
- Prior art keywords
- amino acid
- acid sequences
- polypeptides
- proteins
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500464P | 2011-06-23 | 2011-06-23 | |
| PCT/EP2012/061304 WO2012175400A1 (en) | 2011-06-23 | 2012-06-14 | Serum albumin binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00414A true IN2014CN00414A (OSRAM) | 2015-04-03 |
Family
ID=46298413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN414CHN2014 IN2014CN00414A (OSRAM) | 2011-06-23 | 2012-06-14 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9573992B2 (OSRAM) |
| EP (3) | EP3466972A1 (OSRAM) |
| JP (3) | JP6324887B2 (OSRAM) |
| CN (2) | CN106046168A (OSRAM) |
| AU (1) | AU2012271974B2 (OSRAM) |
| CA (1) | CA2839779C (OSRAM) |
| CY (1) | CY1122691T1 (OSRAM) |
| DK (1) | DK2723771T3 (OSRAM) |
| ES (1) | ES2759936T3 (OSRAM) |
| HR (2) | HRP20192160T1 (OSRAM) |
| HU (1) | HUE047238T2 (OSRAM) |
| IN (1) | IN2014CN00414A (OSRAM) |
| LT (1) | LT2723771T (OSRAM) |
| PL (1) | PL2723771T3 (OSRAM) |
| PT (1) | PT2723771T (OSRAM) |
| SI (1) | SI2723771T1 (OSRAM) |
| WO (1) | WO2012175400A1 (OSRAM) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| KR102240318B1 (ko) * | 2011-06-23 | 2021-04-15 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법 |
| PL2723771T3 (pl) * | 2011-06-23 | 2020-04-30 | Ablynx Nv | Białka wiążące albuminy surowicy |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| JP6219287B2 (ja) * | 2011-09-30 | 2017-10-25 | アブリンクス エン．ヴェー． | ｃ−Ｍｅｔに関連する生物学的物質 |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| HRP20200966T1 (hr) | 2014-05-16 | 2020-10-16 | Ablynx N.V. | Imunoglobulinske varijabilne domene |
| EP3143403B1 (en) | 2014-05-16 | 2021-10-27 | Ablynx N.V. | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| US11426468B2 (en) | 2014-12-19 | 2022-08-30 | Ablynx N.V. | Cysteine linked nanobody dimers |
| JP6986967B2 (ja) | 2015-01-29 | 2021-12-22 | テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー | アルツハイマー病及び関連障害に使用するための抗体分子及びペプチド送達システム |
| WO2016187594A1 (en) | 2015-05-21 | 2016-11-24 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| NO2768984T3 (OSRAM) | 2015-11-12 | 2018-06-09 | ||
| RS62857B1 (sr) * | 2015-11-13 | 2022-02-28 | Ablynx Nv | Unapređeni varijabilni domeni imunoglobulina koji vezuju serumski albumin |
| CA3005488A1 (en) * | 2015-11-18 | 2017-05-26 | Ablynx Nv | Improved serum albumin binders |
| KR102194188B1 (ko) | 2015-11-18 | 2020-12-24 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
| MA43258A (fr) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1/ctla4 |
| GEP20207174B (en) | 2015-11-18 | 2020-11-10 | Merck Sharp & Dohme | Ctla4 binders |
| RU2018122255A (ru) * | 2015-11-27 | 2019-12-19 | Аблинкс Нв | Полипептиды, ингибирующие cd40l |
| CN109641047A (zh) | 2016-05-20 | 2019-04-16 | 哈普恩治疗公司 | 单结构域血清白蛋白结合蛋白质 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CA3029133C (en) | 2016-06-23 | 2024-04-30 | Ablynx N.V. | Improved pharmacokinetic assays for immunoglobulin single variable domains |
| CA3043515A1 (en) | 2016-11-16 | 2018-05-24 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
| BR112019011189A2 (pt) * | 2016-12-07 | 2019-10-08 | Ablynx Nv | domínios variáveis únicos de imunoglobulina que se ligam à albumina sérica melhorada |
| CN107674122A (zh) * | 2016-12-28 | 2018-02-09 | 天津天锐生物科技有限公司 | 一种识别人血清白蛋白的单域抗体 |
| IL312292A (en) * | 2017-01-17 | 2024-06-01 | Ablynx Nv | Improved serum albumin binders |
| FI3571224T3 (fi) * | 2017-01-17 | 2024-11-05 | Ablynx Nv | Parannettuja seerumialbumiinin sitojia |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN |
| US20220099682A9 (en) | 2017-03-31 | 2022-03-31 | Ablynx N.V. | Improved immunogenicity assays |
| CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| TW202000238A (zh) * | 2018-02-26 | 2020-01-01 | 比利時商艾伯林克斯公司 | 編碼肽連接子之經改良核苷酸序列 |
| EP3794038A4 (en) | 2018-05-14 | 2022-02-16 | Harpoon Therapeutics, Inc. | BINDING FRACTION FOR CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス，インク． | Ｄｌｌ３結合タンパク質および使用方法 |
| CN110964107B (zh) * | 2018-09-30 | 2022-08-09 | 苏州康宁杰瑞生物科技有限公司 | Met结合分子、其组合和用途 |
| CN111138537B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 一种抗人血清白蛋白抗体片段、制备方法和应用 |
| CN111138536B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 抗人血清白蛋白单域抗体的制备及其应用 |
| WO2020229844A1 (en) * | 2019-05-15 | 2020-11-19 | Crescendo Biologics Limited | Binding molecules |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| MX2022006881A (es) | 2019-12-06 | 2022-07-11 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l. |
| WO2021110816A1 (en) | 2019-12-06 | 2021-06-10 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23 |
| AU2020400938A1 (en) | 2019-12-09 | 2022-07-28 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP |
| CN110988361B (zh) * | 2019-12-13 | 2020-09-18 | 山东民康生物科技有限公司 | 人血清白蛋白去除试剂盒 |
| MD4087875T2 (ro) | 2020-01-08 | 2025-02-28 | argenx BV | Antagoniști ai receptorului FC neonatal uman (FCRN) pentru tratarea afecțiunilor pemfigusului |
| CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
| WO2021198260A1 (en) | 2020-03-30 | 2021-10-07 | Ablynx Nv | Method for the production and purification of multivalent immunoglobulin single variable domains |
| TW202229338A (zh) | 2020-09-25 | 2022-08-01 | 比利時商艾伯霖克斯公司 | 包含靶向ｉｌ－１３和ｏｘ４０ｌ的免疫球蛋白單可變結構域的多肽 |
| CN112142846B (zh) * | 2020-10-10 | 2022-07-08 | 西北大学 | Aox特异性抗体组合及其制备方法和用途 |
| CN115244076B (zh) | 2020-10-27 | 2023-08-04 | 北京质肽生物医药科技有限公司 | Gdf15融合蛋白及其用途 |
| MX2023007299A (es) | 2020-12-18 | 2023-07-04 | Ablynx Nv | Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta. |
| CA3205422A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| TW202239763A (zh) | 2020-12-18 | 2022-10-16 | 比利時商艾伯霖克斯公司 | 包含靶向ＩＬ－６和ＴＮＦ－α的免疫球蛋白單可變結構域的多肽 |
| WO2023284822A1 (en) * | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
| CN118556077A (zh) * | 2021-11-17 | 2024-08-27 | 南京再明医药有限公司 | 一种多特异性抗体及其药物用途 |
| WO2023111266A1 (en) | 2021-12-17 | 2023-06-22 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123 |
| CN118139892A (zh) * | 2022-01-14 | 2024-06-04 | 浙江道尔生物科技有限公司 | 一种三靶点抗肿瘤药物、其制备方法及其应用 |
| WO2023242247A1 (en) | 2022-06-14 | 2023-12-21 | Ablynx Nv | Immunoglobulin single variable domains targeting t cell receptor |
| WO2023242371A1 (en) * | 2022-06-15 | 2023-12-21 | argenx BV | Ph-dependent hsa-binding molecules and methods of use |
| US20240132624A1 (en) | 2022-07-27 | 2024-04-25 | Ablynx N.V. | Polypeptides binding to a specific epitope of the neonatal fc receptor |
| WO2024084203A1 (en) | 2022-10-18 | 2024-04-25 | Isogenica Limited | Single domain antibodies binding to albumin |
| WO2024131731A1 (zh) | 2022-12-19 | 2024-06-27 | 和铂医药(上海)有限责任公司 | "κ/λ"Fab-Fab串联多特异性结合蛋白及其制备和应用 |
| WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
| WO2024151515A2 (en) | 2023-01-09 | 2024-07-18 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| CN120530125A (zh) * | 2023-01-18 | 2025-08-22 | 北京质肽生物医药科技有限公司 | 融合多肽的液体药物组合物及其使用方法 |
| AR131869A1 (es) * | 2023-02-17 | 2025-05-07 | Ablynx Nv | POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL |
| TW202444757A (zh) | 2023-03-14 | 2024-11-16 | 美商奧迪希治療公司 | 抗cd25抗原結合蛋白及其用途 |
| TW202446782A (zh) | 2023-04-11 | 2024-12-01 | 美商威特拉公司 | 愛帕琳受體促效劑及其用途 |
| WO2024231348A1 (en) | 2023-05-11 | 2024-11-14 | Vib Vzw | Slc4a4/nbce1 inhibitors |
| AR132699A1 (es) | 2023-05-17 | 2025-07-23 | Odyssey Therapeutics Inc | Anticuerpos de dominio único modificados |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| WO2025006846A2 (en) | 2023-06-29 | 2025-01-02 | Odyssey Therapeutics, Inc. | Anti-trailr2 antigen-binding proteins and uses thereof |
| TW202517676A (zh) | 2023-07-05 | 2025-05-01 | 比利時商艾伯霖克斯公司 | 用於治療ＩｇＧ相關疾病及病症之改良ＦｃＲｎ拮抗劑 |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| US20250129145A1 (en) | 2023-09-22 | 2025-04-24 | Ablynx N.V. | Bi- and multivalent albumin binders |
| WO2025080751A2 (en) | 2023-10-13 | 2025-04-17 | Odyssey Therapeutics, Inc. | Anti-cdh17 antigen-binding proteins and uses thereof |
| WO2025085553A1 (en) | 2023-10-16 | 2025-04-24 | Paragon Therapeutics, Inc. | Fcrn antagonists with improved half-life and methods of use |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| WO2025106915A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof |
| WO2025114529A1 (en) | 2023-12-01 | 2025-06-05 | Ablynx Nv | Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| US20250236673A1 (en) | 2023-12-22 | 2025-07-24 | Ablynx N.V. | Protein-based carriers for site-specific amine conjugation |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| DE69330523D1 (de) | 1992-08-21 | 2001-09-06 | Vrije Universiteit Brussel Bru | Immunoglobuline ohne leichte ketten |
| EP0698097B1 (en) | 1993-04-29 | 2001-08-16 | Unilever N.V. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
| EP1900753B1 (en) | 2002-11-08 | 2017-08-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
| US9028816B2 (en) | 2003-01-10 | 2015-05-12 | Ablynx N.V. | Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor |
| CN101035808B (zh) * | 2004-08-05 | 2012-10-31 | 健泰科生物技术公司 | 人源化抗c-met拮抗剂 |
| ES2379283T3 (es) * | 2005-05-18 | 2012-04-24 | Ablynx N.V. | Proteínas de unión a albúmina sérica |
| US7989219B2 (en) | 2005-05-31 | 2011-08-02 | Canon Kabushiki Kaisha | Bispecific capturing molecule |
| WO2006129828A2 (en) | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Target substance capturing molecule |
| AU2007209201A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| RU2008142833A (ru) * | 2006-03-30 | 2010-05-10 | Новартис АГ (CH) | КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ К c-Met |
| US7741273B2 (en) | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| EP2064244B1 (en) | 2006-08-03 | 2019-06-05 | MedImmune Limited | ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF |
| US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
| CA2663042A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| ATE536369T1 (de) | 2006-10-11 | 2011-12-15 | Ablynx Nv | Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung |
| WO2009138519A1 (en) | 2008-05-16 | 2009-11-19 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| AU2008252853B2 (en) | 2007-05-24 | 2011-12-01 | Ablynx N.V. | Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders |
| EP2014681A1 (en) * | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| EP2197491A4 (en) | 2007-09-04 | 2011-01-12 | Univ California | HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER |
| WO2009042589A1 (en) | 2007-09-24 | 2009-04-02 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses thereof |
| US20110189203A1 (en) | 2007-11-27 | 2011-08-04 | Ablynx N.V. | Immunoglobulin constructs |
| BRPI0907648B1 (pt) | 2008-01-29 | 2022-01-11 | Institute Of Molecular Biology And Genetics National Academy Of Science Of Ukraine | Anticorpo isolado humanizado, usos de um anticorpo, métodos para preparar um anticorpo, para gerar anticorpos imunorreativos com slc34a2 e para triar ou identificar agentes ou compostos que modulam slc34a2, composições, ácido nucleico isolado, e, microorganismo hospedeiro |
| CN102112155B (zh) | 2008-06-05 | 2016-08-10 | 埃博灵克斯股份有限公司 | 针对病毒包膜蛋白的氨基酸序列和用于治疗病毒疾病的包含其的多肽 |
| EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| WO2010042815A2 (en) | 2008-10-09 | 2010-04-15 | Duke University | Vhh antibody fragments for use in the detection and treatment of cancer |
| WO2010056550A1 (en) | 2008-10-29 | 2010-05-20 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
| US8779103B2 (en) * | 2009-03-27 | 2014-07-15 | Glaxo Group Limited | Drug fusions and conjugates |
| US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| KR20120102125A (ko) | 2009-12-18 | 2012-09-17 | 사노피 | Ｇｐｖｉ에 대한 신규한 길항제 항체 및 그의 ｆａｂ 단편 및 그의 용도 |
| BR112012022102A2 (pt) | 2010-03-03 | 2017-01-10 | Boehringer Ingelheim Int | polipeptídeos de ligação a a-beta. |
| RS66008B1 (sr) | 2010-03-10 | 2024-10-31 | Genmab As | Monoklonska antitela protiv c-met |
| EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PL2723771T3 (pl) * | 2011-06-23 | 2020-04-30 | Ablynx Nv | Białka wiążące albuminy surowicy |
| KR102240318B1 (ko) | 2011-06-23 | 2021-04-15 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법 |
| US20150344568A1 (en) | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| MX2014001883A (es) | 2011-08-17 | 2014-05-27 | Glaxo Group Ltd | Proteinas y peptidos modificados. |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
-
2012
- 2012-06-14 PL PL12727658T patent/PL2723771T3/pl unknown
- 2012-06-14 JP JP2014516279A patent/JP6324887B2/ja active Active
- 2012-06-14 CN CN201610392570.9A patent/CN106046168A/zh active Pending
- 2012-06-14 EP EP18205150.8A patent/EP3466972A1/en active Pending
- 2012-06-14 IN IN414CHN2014 patent/IN2014CN00414A/en unknown
- 2012-06-14 ES ES12727658T patent/ES2759936T3/es active Active
- 2012-06-14 US US14/128,719 patent/US9573992B2/en active Active
- 2012-06-14 HU HUE12727658A patent/HUE047238T2/hu unknown
- 2012-06-14 HR HRP20192160TT patent/HRP20192160T1/hr unknown
- 2012-06-14 WO PCT/EP2012/061304 patent/WO2012175400A1/en active Application Filing
- 2012-06-14 CN CN201280030647.8A patent/CN103619878B/zh active Active
- 2012-06-14 PT PT127276582T patent/PT2723771T/pt unknown
- 2012-06-14 LT LT12727658T patent/LT2723771T/lt unknown
- 2012-06-14 SI SI201231696T patent/SI2723771T1/sl unknown
- 2012-06-14 AU AU2012271974A patent/AU2012271974B2/en active Active
- 2012-06-14 EP EP12727658.2A patent/EP2723771B1/en active Active
- 2012-06-14 EP EP23159592.7A patent/EP4218933A1/en active Pending
- 2012-06-14 DK DK12727658T patent/DK2723771T3/da active
- 2012-06-14 CA CA2839779A patent/CA2839779C/en active Active
- 2012-06-25 HR HRP20170535TT patent/HRP20170535T4/hr unknown
-
2017
- 2017-01-03 US US15/397,313 patent/US20170210789A1/en not_active Abandoned
-
2018
- 2018-04-11 JP JP2018076201A patent/JP6843090B2/ja active Active
-
2019
- 2019-12-10 CY CY20191101299T patent/CY1122691T1/el unknown
-
2021
- 2021-02-22 JP JP2021026177A patent/JP7304375B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012175400A1 (en) | 2012-12-27 |
| JP7304375B2 (ja) | 2023-07-06 |
| HRP20170535T1 (hr) | 2017-06-16 |
| CA2839779C (en) | 2020-10-06 |
| PT2723771T (pt) | 2019-12-11 |
| CN106046168A (zh) | 2016-10-26 |
| EP2723771A1 (en) | 2014-04-30 |
| CY1122691T1 (el) | 2021-03-12 |
| EP4218933A1 (en) | 2023-08-02 |
| JP6324887B2 (ja) | 2018-05-16 |
| EP2723771B1 (en) | 2019-09-11 |
| JP2021088585A (ja) | 2021-06-10 |
| JP2014520129A (ja) | 2014-08-21 |
| DK2723771T3 (da) | 2019-12-02 |
| EP3466972A1 (en) | 2019-04-10 |
| PL2723771T3 (pl) | 2020-04-30 |
| CN103619878A (zh) | 2014-03-05 |
| SI2723771T1 (sl) | 2019-12-31 |
| ES2759936T3 (es) | 2020-05-12 |
| JP2018127478A (ja) | 2018-08-16 |
| HRP20192160T1 (hr) | 2020-02-21 |
| US9573992B2 (en) | 2017-02-21 |
| CN103619878B (zh) | 2016-10-26 |
| JP6843090B2 (ja) | 2021-03-17 |
| AU2012271974B2 (en) | 2017-01-12 |
| AU2012271974A1 (en) | 2013-12-12 |
| CA2839779A1 (en) | 2012-12-27 |
| US20170210789A1 (en) | 2017-07-27 |
| LT2723771T (lt) | 2019-12-10 |
| HUE047238T2 (hu) | 2020-04-28 |
| HRP20170535T4 (hr) | 2022-08-19 |
| US20140228546A1 (en) | 2014-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN00414A (OSRAM) | ||
| IN2014CN00437A (OSRAM) | ||
| WO2008028977A3 (en) | Serum albumin binding proteins with long half-lives | |
| PH12019500596B1 (en) | Recombinant binding proteins and their use | |
| MX2013012844A (es) | Secuencias de aminoacidos dirigidas contra il-17a, il-17f y/o il-17a/f y polipeptidos que comprenden las mismas. | |
| WO2013040093A3 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
| PH12013500395B1 (en) | 4-1bb binding molecules | |
| CA2818990C (en) | Designed repeat proteins binding to serum albumin | |
| PH12012502272A1 (en) | Biological materials related to her3 | |
| HK1214739A1 (zh) | 工程化的分泌蛋白质和方法 | |
| MX350962B (es) | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. | |
| MX2015008446A (es) | Composiciones de proteinas de union multivalentes. | |
| MX2014011459A (es) | Proteinas nutritivas cargadas y metodos. | |
| IN2014DN05756A (OSRAM) | ||
| WO2013184938A3 (en) | Fusion polypeptides comprising mucin-domain polypeptide linkers | |
| BR112014032316A2 (pt) | proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta | |
| WO2008043822A3 (en) | Amino acid sequences that bind to a desired molecule in a conditional manner | |
| DK1888641T3 (da) | Serumalbuminbindende proteiner | |
| HK1206764A1 (en) | Nutritive proteins and methods | |
| MX2024005945A (es) | Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos. | |
| MX366178B (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
| PH12014501200A1 (en) | Bacteriophage gene 3 protein compositions and use as amyloid binding agents | |
| HK1206763A1 (en) | Charged nutritive fragments, proteins and methods | |
| WO2014151834A3 (en) | Methods and compositions relating to anti-ccr7 antigen binding proteins | |
| MX2012004295A (es) | Composicion para el tratamiento de esclerosis multiple. |